New China price probe a policy portent?
This article was originally published in Scrip
Executive Summary
China's National Development and Reform Commission (NDRC) has initiated a new three-month long investigation into the cost and price of drugs supplied by 60 selected pharmaceutical companies nationwide, with the ultimate aim of adjusting the prices of medicines covered by the national healthcare scheme.